CY1121112T1 - Χιμαιρικοι λοιμωδεις κλωνοι dna του κυκλοϊου των χοιρων και χρησεις εξ αυτων - Google Patents

Χιμαιρικοι λοιμωδεις κλωνοι dna του κυκλοϊου των χοιρων και χρησεις εξ αυτων

Info

Publication number
CY1121112T1
CY1121112T1 CY181101151T CY181101151T CY1121112T1 CY 1121112 T1 CY1121112 T1 CY 1121112T1 CY 181101151 T CY181101151 T CY 181101151T CY 181101151 T CY181101151 T CY 181101151T CY 1121112 T1 CY1121112 T1 CY 1121112T1
Authority
CY
Cyprus
Prior art keywords
infectious
pathogen
chimeric
cyclope
dogs
Prior art date
Application number
CY181101151T
Other languages
English (en)
Inventor
Xiang-Jin Meng
Martijn Fenaux
Patrick G Halbur
Original Assignee
Virginia Tech Intellectual Properties Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Virginia Tech Intellectual Properties Inc filed Critical Virginia Tech Intellectual Properties Inc
Publication of CY1121112T1 publication Critical patent/CY1121112T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/10011—Circoviridae
    • C12N2750/10061—Methods of inactivation or attenuation

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Η παρούσα εφεύρεση σχετίζεται με ένα προϊόν ανοσογόνου πολυπεπτιδίου το οποίο είναι απολήψιμο από έκφραση κλώνων λοιμώδους χιμαιρικού DNA του κυκλοϊού των χοιροειδών (PCV). Η παρούσα εφεύρεση σχετίζεται επίσης με αντιστοιχούντα εμβόλια και μέσα προστασίας χοίρων έναντι ιικής λοίμωξης ή του συνδρόμου πολλαπλοσυστημικής απίσθμασης μετά τον απογαλακτισμό (PMWS) που προκαλείται από PCV. Ο νέος κλώνος χιμαιρικού λοιμώδους DNA κατασκευάζεται από τον μη-παθογόνο PCV1 στον οποίο το ανοσογόνο γονίδιο ORF του παθογόνου PCV2 αντικαθιστά ένα γονίδιο του μη-παθογόνου PCV1, προτιμώμενα στην ίδια θέση.
CY181101151T 2001-12-12 2018-11-05 Χιμαιρικοι λοιμωδεις κλωνοι dna του κυκλοϊου των χοιρων και χρησεις εξ αυτων CY1121112T1 (el)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US34077501P 2001-12-12 2001-12-12
US42484002P 2002-11-08 2002-11-08
US10/314,512 US7276353B2 (en) 2001-12-12 2002-12-09 Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
EP02797280A EP1487483B1 (en) 2001-12-12 2002-12-11 Chimeric infectious dna clones of porcine circovirus and uses thereof
PCT/US2002/039646 WO2003049703A2 (en) 2001-12-12 2002-12-11 Chimeric infectious dna clones, chimeric porcine circoviruses and uses thereof

Publications (1)

Publication Number Publication Date
CY1121112T1 true CY1121112T1 (el) 2019-12-11

Family

ID=27405726

Family Applications (3)

Application Number Title Priority Date Filing Date
CY20111100127T CY1111167T1 (el) 2001-12-12 2011-02-03 Χιμαιρικοι λοιμωδεις κλωνοι dna του κυκλοϊου των χοιρων και χρησεις εξ αυτων
CY2011004C CY2011004I2 (el) 2001-12-12 2011-05-06 Χιμαιρικοι λοιμωδεις κλωνοι dna του κυκλοϊου των χοιρων και χρησεις εξ αυτων
CY181101151T CY1121112T1 (el) 2001-12-12 2018-11-05 Χιμαιρικοι λοιμωδεις κλωνοι dna του κυκλοϊου των χοιρων και χρησεις εξ αυτων

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CY20111100127T CY1111167T1 (el) 2001-12-12 2011-02-03 Χιμαιρικοι λοιμωδεις κλωνοι dna του κυκλοϊου των χοιρων και χρησεις εξ αυτων
CY2011004C CY2011004I2 (el) 2001-12-12 2011-05-06 Χιμαιρικοι λοιμωδεις κλωνοι dna του κυκλοϊου των χοιρων και χρησεις εξ αυτων

Country Status (30)

Country Link
US (1) US7276353B2 (el)
EP (5) EP2263689B1 (el)
JP (1) JP4623964B2 (el)
KR (1) KR101014544B1 (el)
CN (2) CN103536911B (el)
AT (1) ATE487490T1 (el)
AU (3) AU2002362147C1 (el)
BE (1) BE2011C008I2 (el)
BR (1) BRPI0214919B1 (el)
CA (2) CA2784260C (el)
CO (1) CO5590938A2 (el)
CY (3) CY1111167T1 (el)
DE (2) DE60238278D1 (el)
DK (3) DK1487483T3 (el)
ES (3) ES2694505T3 (el)
HK (1) HK1151988A1 (el)
HR (3) HRP20040626B9 (el)
HU (5) HU231162B1 (el)
LT (1) LT2264050T (el)
LU (1) LU91814I2 (el)
ME (1) ME00126B (el)
MX (1) MXPA04005364A (el)
NL (1) NL300480I2 (el)
NZ (2) NZ567688A (el)
PL (3) PL215058B1 (el)
PT (3) PT2264050T (el)
RS (1) RS51288B (el)
SI (3) SI2263689T1 (el)
TW (1) TWI314580B (el)
WO (1) WO2003049703A2 (el)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2772047B1 (fr) * 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US7279166B2 (en) * 2001-12-12 2007-10-09 Virginia Tech Intellectual Properties, Inc. Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
CN1749397B (zh) * 2004-08-18 2010-12-08 金宁一 共表达猪圆环病毒及口蹄疫病毒的二联重组活载体疫苗
US7833707B2 (en) 2004-12-30 2010-11-16 Boehringer Ingelheim Vetmedica, Inc. Methods of overexpression and recovery of porcine circovirus type 2 ORF2
UA95602C2 (ru) 2004-12-30 2011-08-25 Берингер Ингельхейм Ветмедика, Инк. Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7700285B1 (en) 2005-12-29 2010-04-20 Boehringer Ingelheim Vetmedica, Inc. PCV2 immunogenic compositions and methods of producing such compositions
CN103285387B (zh) 2004-12-30 2017-07-25 勃林格殷格翰动物保健有限公司 Pcv2免疫原性组合物和产生这种组合物的方法
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
CN1328373C (zh) * 2005-04-07 2007-07-25 南京农业大学 猪ⅱ型圆环病毒重组腺病毒
EP1896069B1 (en) * 2005-06-24 2013-03-13 Intervet International BV Inactivated chimeric vaccines and related methods of use
JP5106398B2 (ja) 2005-09-09 2012-12-26 インターベツト・インターナシヨナル・ベー・ベー Ｐｃｖ−２ワクチン
EP3868400A1 (en) 2005-12-29 2021-08-25 Boehringer Ingelheim Animal Health USA Inc. Multivalent pcv2 immunogenic compositions and methods of producing such compositions
PT2371383E (pt) * 2005-12-29 2015-11-24 Boehringer Ingelheim Vetmed Utilização de uma composição imunogénica de pcv2 para atenuar os sintomas clínicos em porcos
JP4625485B2 (ja) * 2006-09-29 2011-02-02 財団法人大阪産業振興機構 高病原性トリインフルエンザウイルスに対するモノクローナル抗体
WO2008064299A2 (en) * 2006-11-22 2008-05-29 Boehringer Ingelheim Vetmedica, Inc. Methods of reducing porcine circovirus-associated disease outbreaks
EP2101815A4 (en) 2006-12-11 2010-10-06 Boehringer Ingelheim Vetmed EFFICIENT PROCESS FOR THE TREATMENT OF PORCINE CIRCOVIRUS AND LAWSONIA INTRACELLULARIS INFECTIONS
US8865183B2 (en) * 2006-12-15 2014-10-21 Boehringer Ingelheim Vetmedica, Inc. Treatment of pigs with PCV2 antigent
EP1941903A1 (en) 2007-01-03 2008-07-09 Boehringer Ingelheim Vetmedica Gmbh Prophylaxis and treatment of PRDC
EP1958644A1 (en) 2007-02-13 2008-08-20 Boehringer Ingelheim Vetmedica Gmbh Prevention and treatment of sub-clinical pcvd
US20080299141A1 (en) * 2007-05-30 2008-12-04 Wyeth Raccoon Poxvirus Expressing Genes of Porcine Virus
US20090017064A1 (en) * 2007-07-10 2009-01-15 Wyeth Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en) * 2007-09-04 2010-11-09 Boehringer Ingelheim Vetmedica, Inc. Reduction of concomitant infections in pigs by the use of PCV2 antigen
RU2489164C9 (ru) * 2007-11-06 2014-01-20 ВАЙЕТ ЭлЭлСи АВИРУЛЕНТНАЯ АДЪЮВАНТНАЯ ЖИВАЯ ВАКЦИНА ПРОТИВ Mycoplasma hyopneumoniae
CN101932700A (zh) * 2007-12-21 2010-12-29 惠氏有限责任公司 对猪进行抗猪圆环病毒免疫的方法和组合物
BRPI0821456A2 (pt) * 2007-12-31 2015-06-16 Boehring Ingelheim Vetmedica Inc Partícula similar à pcv2 orf2 com inserção de aminoácido estranho
EP2242511A4 (en) 2008-01-23 2012-10-24 Boehringer Ingelheim Vetmed IMMUNOGENIC COMPOSITIONS OF MYCOPLASMA HYOPNEUMONIAE PCV2, AND METHODS FOR PRODUCING SUCH COMPOSITIONS
US20110033495A1 (en) * 2008-02-15 2011-02-10 Boehringer Ingelheim Vetmedica, Inc. Methods and compositions for reducing the impact of enteric diseases
JP2011519273A (ja) * 2008-04-16 2011-07-07 ヴァージニア テック インテレクチュアル プロパティーズ，インコーポレーテッド キメラブタサーコウイルスＰＣＶ２Ｇｅｎ−１Ｒｅｐおよびその使用
AR078253A1 (es) 2009-09-02 2011-10-26 Boehringer Ingelheim Vetmed Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
PL2547770T3 (pl) 2010-03-16 2020-06-29 Virginia Tech Intellectual Properties, Inc. Szczepionka zawierająca żywy atenuowany chimeryczny cirkowirus świń
TWI508974B (zh) 2010-12-22 2015-11-21 Sbc Virbac Ltd 豬第二型環狀病毒(Porcine Circovirus Type 2)、含彼之免疫組合物、檢測套組及其應用
WO2012091128A1 (ja) 2010-12-28 2012-07-05 Ｊｘ日鉱日石エネルギー株式会社 有機化合物の水素化装置及び水素化方法
HUP1100470A2 (en) * 2011-08-30 2013-03-28 Mezoegazdasagi Biotechnologiai Kutatokoezpont Nanoparticle-based veterinary vaccine
UA113192C2 (xx) 2011-12-06 2016-12-26 Імуногенна композиція проти цирковірусу свиней типу 2 (pcv2)
US9120859B2 (en) 2012-04-04 2015-09-01 Zoetis Services Llc Mycoplasma hyopneumoniae vaccine
UA114504C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv, mycoplasma hyopneumoniae та prrs
UA114503C2 (uk) 2012-04-04 2017-06-26 Зоетіс Сервісіз Ллс Комбінована вакцина pcv та mycoplasma hyopneumoniae
KR102217387B1 (ko) * 2013-03-11 2021-02-19 주식회사 중앙백신연구소 재조합 효모 전세포(yeast whole cell)을 이용한 돼지 써코바이러스(PCV2) 서브유닛 백신과 그의 제조 방법
KR102319843B1 (ko) 2013-09-25 2021-10-29 조에티스 서비시즈 엘엘씨 Pcv2b 분지형 백신 조성물 및 사용 방법
KR20220083861A (ko) 2013-10-02 2022-06-20 베링거 인겔하임 애니멀 헬스 유에스에이 인크. Ｐｃｖ2 ｏｒｆ2 단백질 변이체 및 이로 이루어진 바이러스 유사 입자
CN103602759B (zh) * 2013-11-22 2015-09-23 福建省农业科学院畜牧兽医研究所 一种区别鸭圆环病毒和鹅圆环病毒的pcr-rflp方法
DK3076996T3 (en) 2013-12-03 2020-03-09 Intervet Int Bv Vaccine mod porcint circovirus type 2
JP2019507784A (ja) * 2016-03-07 2019-03-22 ヴァージニア テック インテレクチュアル プロパティーズ，インコーポレーテッド キメラブタサーコウイルス２型（ｐｃｖ２）ワクチン
CN106497892A (zh) * 2016-09-07 2017-03-15 扬州大学 带KT3标签的重组病毒rPCV2‑KT3的构建方法
EA202092216A1 (ru) 2018-03-26 2021-06-11 Бёрингер Ингельхайм Энимал Хелс Ю-Эс-Эй Инк. Способ получения иммуногенной композиции
CN112898435B (zh) * 2021-01-14 2023-03-31 山西农业大学 一种可溶性融合蛋白DT390-Cap及其制备方法与应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2769322B1 (fr) 1997-10-03 2002-03-08 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostic
FR2769321B1 (fr) 1997-10-03 2001-10-26 Merial Sas Nouveaux circovirus porcins, vaccins et reactifs de diagnostics
UA78180C2 (uk) 1997-10-03 2007-03-15 Меріаль Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US6517843B1 (en) 1999-08-31 2003-02-11 Merial Reduction of porcine circovirus-2 viral load with inactivated PCV-2
US6391314B1 (en) * 1997-10-03 2002-05-21 Merial Porcine circoviruses vaccines diagnostic reagents
FR2781159B1 (fr) * 1998-07-06 2000-10-06 Merial Sas Vaccin circovirus et parvovirus porcin
FR2772047B1 (fr) 1997-12-05 2004-04-09 Ct Nat D Etudes Veterinaires E Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
KR100879650B1 (ko) * 1997-12-11 2009-01-20 유니버시티 오브 사스카췌완 돼지로부터의 이유후 다기관계작용성 소모 증후군 바이러스
AU770002B2 (en) 1998-03-13 2004-02-12 University Of Georgia Research Foundation, Inc., The Vaccines against circovirus infections
US6497883B1 (en) * 1999-06-10 2002-12-24 Merial Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en) 1999-06-10 2005-09-13 Merial DNA vaccine-PCV
CA2413265A1 (en) 2000-05-03 2001-11-08 University Of Guelph Porcine adenovirus type 5 vector and vaccine
EP1283718A2 (en) * 2000-05-24 2003-02-19 Merial Porcine reproductive and respiratory syndrome virus (prrsv) recombinant avipoxvirus vaccine
CA2410229A1 (en) 2000-06-15 2001-12-20 Purdue Research Foundation Vaccine for congenital tremors in pigs
DE10044648A1 (de) * 2000-09-08 2002-03-21 Aventis Behring Gmbh Verfahren zur Vermehrung oder zur Entfernung von Cirocoviren aus biologischem Material
JP4038127B2 (ja) * 2001-03-27 2008-01-23 ユニバーシティ オブ サスカチュワン サーコウイルスの培養方法
AUPR567401A0 (en) 2001-06-14 2001-07-12 University Of Melbourne, The Circovirus vaccines

Also Published As

Publication number Publication date
LU91814I2 (fr) 2011-07-04
EP3388515A1 (en) 2018-10-17
HRP20140002A2 (hr) 2014-11-07
EP2263689A3 (en) 2011-04-20
US20030170270A1 (en) 2003-09-11
HRP20040626B9 (hr) 2016-09-23
DE122011100001I1 (de) 2011-09-08
CA2784260A1 (en) 2003-06-19
BE2011C008I2 (el) 2022-02-02
EP1487483B1 (en) 2010-11-10
EP2263689B1 (en) 2014-11-12
PL395510A1 (pl) 2011-12-19
CA2784260C (en) 2016-05-17
RS51704A (en) 2006-10-27
PL374382A1 (en) 2005-10-17
EP2264050A3 (en) 2011-04-20
HUP0501000A2 (en) 2007-12-28
EP2263690A2 (en) 2010-12-22
NZ533256A (en) 2008-06-30
DK2263689T3 (en) 2015-02-02
EP2263689A2 (en) 2010-12-22
CA2469599C (en) 2012-10-23
HU231018B1 (hu) 2019-11-28
CN103536911A (zh) 2014-01-29
MXPA04005364A (es) 2004-09-27
DK2264050T3 (en) 2018-12-03
WO2003049703A8 (en) 2005-12-01
BRPI0214919B1 (pt) 2015-09-15
RS51288B (sr) 2010-12-31
CN1620310A (zh) 2005-05-25
HUS2100036I1 (hu) 2021-09-28
AU2002362147B2 (en) 2008-03-13
AU2011200843A1 (en) 2011-03-17
HU231162B1 (hu) 2021-05-28
HRP20040626A2 (en) 2006-03-31
PL215058B1 (pl) 2013-10-31
AU2008202333B2 (en) 2010-11-25
KR20040086243A (ko) 2004-10-08
EP2263690A3 (en) 2011-06-08
US7276353B2 (en) 2007-10-02
HU230576B1 (hu) 2017-01-30
ME00126B (me) 2010-10-10
ES2355814T3 (es) 2011-03-31
HRP20140003A2 (hr) 2014-11-07
PT2263689E (pt) 2015-02-13
HRP20140003B1 (hr) 2020-10-16
CY1111167T1 (el) 2014-04-09
WO2003049703A3 (en) 2004-09-30
WO2003049703A2 (en) 2003-06-19
AU2011200843B2 (en) 2012-01-19
CY2011004I1 (el) 2014-04-09
KR101014544B1 (ko) 2011-02-16
SI2263689T1 (sl) 2015-03-31
LT2264050T (lt) 2018-11-26
AU2002362147A1 (en) 2003-06-23
PL214803B1 (pl) 2013-09-30
TW200307042A (en) 2003-12-01
HRP20040626B1 (hr) 2016-08-26
HK1151988A1 (en) 2012-02-17
HRP20140002B1 (hr) 2020-10-16
SI1487483T1 (sl) 2011-03-31
EP2264050B1 (en) 2018-08-08
AU2008202333A1 (en) 2008-06-19
CN103536911B (zh) 2019-09-13
EP2264050A2 (en) 2010-12-22
DE60238278D1 (de) 2010-12-23
MEP17708A (en) 2010-06-10
EP1487483A2 (en) 2004-12-22
TWI314580B (en) 2009-09-11
AU2002362147C1 (en) 2012-05-17
CO5590938A2 (es) 2005-12-30
ATE487490T1 (de) 2010-11-15
PL395509A1 (pl) 2011-12-19
PT2264050T (pt) 2018-11-21
CY2011004I2 (el) 2015-10-07
ES2694505T3 (es) 2018-12-21
HU228584B1 (en) 2013-04-29
PT1487483E (pt) 2011-02-10
NL300480I2 (el) 2016-11-01
JP2005511075A (ja) 2005-04-28
CA2469599A1 (en) 2003-06-19
ES2529726T3 (es) 2015-02-25
CN1620310B (zh) 2014-11-26
HUP1300097A2 (en) 2007-12-28
EP1487483A4 (en) 2006-02-15
DK1487483T3 (da) 2011-02-21
BR0214919A (pt) 2006-05-30
NZ567688A (en) 2009-09-25
JP4623964B2 (ja) 2011-02-02
SI2264050T1 (sl) 2018-12-31

Similar Documents

Publication Publication Date Title
CY1121112T1 (el) Χιμαιρικοι λοιμωδεις κλωνοι dna του κυκλοϊου των χοιρων και χρησεις εξ αυτων
CY1113530T1 (el) Εμβολιο εναντι του αναπαραγωγικου και αναπνευστικου συνδρομου των χοιρων, βασισμενο στο απομονωθεν στελεχος ja-142
ATE527281T1 (de) Impfstoffe gegen aids umfassend cmv/r nucleinsäurekonstrukte
EA200501890A1 (ru) Вирусы гриппа высокого титра для приготовления вакцин и генной терапии
NL300364I1 (nl) Recombinante influenzavirussen voor vaccins en gentherapie
DK1796717T3 (da) Kombinationsvaccine
PT1370668E (pt) Vacinas de vector baseadas em leporipox
FR2724385B1 (fr) Vaccin de la peritonite infectieuse feline.
CY1116098T1 (el) Χιμαιρικοι μολυσματικοι κλωνοι dna του κυκλοϊου των χοιρων και χρησεις εξ αυτων
ATE330969T1 (de) Impfstoffe basierend auf mutanten des virus der infektiösen bursal-krankheit
UA122732U (uk) Вакцина проти репродуктивно-респіраторного синдрому цирковірусної та парвовірусної інфекції свиней асоційована інактивована емульсована
CY1116483T1 (el) Εμβολιο χοιρειου κυκλοϊου σε ανασυνδυασμενο ιο της ευλογιας